In Friday’s Wall Street session, Sarepta Therapeutics Inc (NASDAQ:SRPT) shares traded at $20.77, up 20.08% from the previous session.
SRPT stock price is now 1.18 away from the 50-day moving average and May 06 AMC away from the 200-day moving average. The market capitalization of the company currently stands at $1.97B.
On June 18, 2025, TD Cowen Downgraded its previous ‘Buy’ rating to ‘Hold’ on the stock keeping its target price maintained at $24, while ‘Wolfe Research’ rates the stock as ‘Peer Perform’
In other news, Nicaise Claude, Director sold 2,491 shares of the company’s stock on Mar 12 ’25. The stock was sold for $248,203 at an average price of $99.64. Upon completion of the transaction, the Director now directly owns 27,812 shares in the company, valued at $0.58 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Mar 12 ’25, Director Nicaise Claude bought 2,491 shares of the business’s stock. A total of $248,226 was incurred on buying the stock at an average price of $99.65. A total of 4.99% of the company’s stock is owned by insiders.
During the past 12 months, Sarepta Therapeutics Inc has had a low of $18.30 and a high of $173.25.
The net profit margin was -11.12% and return on equity was -23.61% for SRPT.
